ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

ClinicalTrials.gov ID: NCT01367002

Public ClinicalTrials.gov record NCT01367002. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 10:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma

Study identification

NCT ID
NCT01367002
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Yale University
Other
Enrollment
61 participants

Conditions and interventions

Interventions

  • Carboplatin/Paclitaxel Drug
  • Trastuzumab Drug

Drug

Eligibility (public fields only)

Age range
Not listed
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2011
Primary completion
Jun 29, 2022
Completion
Jun 29, 2022
Last update posted
May 16, 2023

2011 – 2022

United States locations

U.S. sites
20
U.S. states
11
U.S. cities
19
Facility City State ZIP Site status
St. Joseph's Hospital and Medical Center Phoenix Arizona 85013
University of Arizona Cancer Center Tucson Arizona 85724
John Muir Clinical Research Center Concord California 94520
Women's Cancer Research Foundation Newport Beach California 92663
Penrose St. Francis Hospital Colorado Springs Colorado 80907
Danbury Hospital Danbury Connecticut 06810
University of Connecticut Health Center Farmington Connecticut 06030
The Hospital of Central Connecticut New Britain Connecticut 06050
Smilow Cancer Hospital at Yale New Haven New Haven Connecticut 06510
The University of Chicago Medicine Chicago Illinois 60637
Greater Baltimore Medical Center Baltimore Maryland 21204
Walter Reed National Military Medical Center Bethesda Maryland 20889-5600
Holy Cross Hospital Silver Spring Maryland 20910
University of Maryland Medical Center Silver Spring Maryland 20910
Jersey Shore University Medical Center Neptune City New Jersey 07753
Montefiore Medical Center The Bronx New York 10461
Duke University School of Medicine Durham North Carolina 27710
Cleveland Clinic Cleveland Ohio 44195
The Ohio State University Hilliard Ohio 43026
University of Virginia Charlottesville Virginia 22908

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01367002, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 16, 2023 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01367002 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →